Saturday, October 24, 2009
Erythropoietin: a multimodal neuroprotective agent
Nadiya Byts and Anna-Leena Siren
Experimental & Translational Stroke Medicine 2009, 1:4doi:10.1186/2040-7378-1-4
Published: 21 October 2009
OPEN ACCESS
Abstract (provisional)
The tissue protective functions of the hematopoietic growth factor erythropoietin (EPO) are independent of its action on erythropoiesis. EPO and its receptors (EPOR) are expressed in multiple brain cells during brain development and upregulated in the adult brain after injury. Peripherally administered EPO crosses the blood-brain barrier and activates in the brain anti-apoptotic, anti-oxidant and anti-inflammatory signaling in neurons, glial and cerebrovascular endothelial cells and stimulates angiogenesis and neurogenesis. These mechanisms underlie its potent tissue protective effects in experimental models of stroke, cerebral hemorrhage, traumatic brain injury, neuroinflammatory and neurodegenerative disease. The preclinical data in support of the use of EPO in brain disease have already been translated to first clinical pilot studies with encouraging results with the use of EPO as a neuroprotective agent.
The complete article is available as a provisional PDF . CLICK HERE
Experimental & Translational Stroke Medicine 2009, 1:4doi:10.1186/2040-7378-1-4
Published: 21 October 2009
OPEN ACCESS
Abstract (provisional)
The tissue protective functions of the hematopoietic growth factor erythropoietin (EPO) are independent of its action on erythropoiesis. EPO and its receptors (EPOR) are expressed in multiple brain cells during brain development and upregulated in the adult brain after injury. Peripherally administered EPO crosses the blood-brain barrier and activates in the brain anti-apoptotic, anti-oxidant and anti-inflammatory signaling in neurons, glial and cerebrovascular endothelial cells and stimulates angiogenesis and neurogenesis. These mechanisms underlie its potent tissue protective effects in experimental models of stroke, cerebral hemorrhage, traumatic brain injury, neuroinflammatory and neurodegenerative disease. The preclinical data in support of the use of EPO in brain disease have already been translated to first clinical pilot studies with encouraging results with the use of EPO as a neuroprotective agent.
The complete article is available as a provisional PDF . CLICK HERE
Direct Fe2+ Sensing by Iron-responsive Messenger RNA·Repressor Complexes Weakens Binding*
October 30, 2009 The Journal of Biological Chemistry, 284, 30122-30128.
1. Mateen A. Khan‡, 2. William E. Walden§, 3. Dixie J. Goss‡,1 and 4. Elizabeth C. Theil¶‖,2
1. From the ‡Department of Chemistry, Hunter College, City University of New York, New York, New York 10065,
2. the §Department of Microbiology and Immunology, University of Illinois, Chicago, Illinois 60612-7334,
3. the ¶Children's Hospital Oakland Research Institute, Oakland, California 94609, and
4. the ‖Department of Nutrition Science and Toxicolology, University of California, Berkeley, California 94720
Keywords: Fe2+, ferritin, mitochondrial aconitase messenger, regulatory proteins (IRPs),iron-induced mRNA translation.
1. Mateen A. Khan‡, 2. William E. Walden§, 3. Dixie J. Goss‡,1 and 4. Elizabeth C. Theil¶‖,2
1. From the ‡Department of Chemistry, Hunter College, City University of New York, New York, New York 10065,
2. the §Department of Microbiology and Immunology, University of Illinois, Chicago, Illinois 60612-7334,
3. the ¶Children's Hospital Oakland Research Institute, Oakland, California 94609, and
4. the ‖Department of Nutrition Science and Toxicolology, University of California, Berkeley, California 94720
Keywords: Fe2+, ferritin, mitochondrial aconitase messenger, regulatory proteins (IRPs),iron-induced mRNA translation.
Subscribe to:
Posts (Atom)
